BIOPHYTIS SA

Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-Meter Walk Test (400MWT), the primary endpoint of the study, including in sub-populations at higher risk of mobility disability,…

PARIS and CAMBRIDGE, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative…

The independent DMC (Data Monitoring Committee) recommends continuation of Part 2 of the Phase 2-3 Study (“the COVA Study”) without any protocol amendmentThe second Interim Analysis (“IA2”) based on 155 hospitalized patients shows no…

The independent DMC (Data Monitoring Committee) of the COVA study recommends to continue patients recruitment into Part 2 of the phase 2-3 study following randomization of the first 155 patientsEfficacy data from the second Interim…

Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the studySarconeos (BIO101) showed a very good safety profile at the doses of 175…

PARIS and CAMBRIDGE, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), a clinical-stage biotechnology company focused on the development of therapeutics…

The Company signed contracts for the manufacturing of registration batches in view of the potential application for Emergency Use Authorization to FDA and/or Conditional Marketing Authorization to EMAThe 155th patient has completed…

PARIS and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”),a clinical-stage biotechnology company focused on the development of therapeutics…

This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy dataThe Company is to report the recommendation from the DMC based on its review of second interim analysis by end…